Jiang, Sha-Sha Deng, Bo Feng, Yong-Geng Qian, Kai Tan, Qun-You Wang, Ru-Wen
Published in
BMC Pulmonary Medicine
BackgroundOur study aimed to verify the prognostic value of circulating tumor cells (CTCs) prior to initial treatment on survival of non-small cell lung cancer (NSCLC) by using meta-analysis and system review of published studies.Materials and methodsThe PubMed, EMBASE and Cochrane Library were searched, respectively, to identify all studies that a...
Sheng, Liming Cui, Xiaoying Cheng, Lei Chen, Ying Du, Xianghui
Published in
Radiation Oncology
ObjectivesTo observe the risk factors affecting the occurrence of RP after gemcitabine-based induction chemotherapy.MethodsBetween January 2010 and December 2017, patients with NSCLC received gemcitabine or docetaxel chemotherapy, followed by radiotherapy at Zhejiang cancer hospital were enrolled in this study. Patients were treated with gemcitabin...
Reinmuth, Niels
Published in
Karger Kompass Pneumologie
Background: The role of microRNA-133a (miR-133a) in non-small cell lung cancers (NSCLCs) is controversial. Thus, we conducted a comprehensive study based on meta-analysis and The Cancer Genome Atlas (TCGA) database. Methods: Publications were searched in both English and Chinese databases, and meta-analysis was performed using Stata 12.0. The clini...
Xie, Yuping Zhao, Fen Zhang, Ping Duan, Ping Shen, Yangmei
Published in
Human cell
Non-small cell lung cancer (NSCLC) is a malignant tumor with a high fatality, low overall cure, and survival rates worldwide. When only palliative therapy is available, the disease leads to malignant proliferation. Previous studies showed miR-29b serves as an NSCLC suppressor by inhibiting cells proliferation, migration, and invasion. However, the ...
Alzahrani, Ali M. Alzahrani, Asma A. Alsharm, Abdullah A.
Published in
Case Reports in Oncology
The most common side effect for cancer patients using epidermal growth factor receptor inhibitors (EGFRI) is the development of an itchy papulopustular rash. In severe cases, the patients are forced to stop taking the medications, hence affecting treatment outcomes. We herein report a case of a 50-year-old patient who developed a papulopustular ras...
Zhu, Kegan Ding, Hanying Yu, Ao Liao, Zhicong Fu, Zheng Hong, Yeting Wang, Xiaojun Zhang, Chen-Yu Chen, Xi
Published in
ExRNA
MicroRNAs (miRNAs) function as important oncogenes or tumor suppressors in each stage of cancer development. While previous studies focused on the individual miRNA and its specific target gene, the cooperative functions of miRNA-3p and miRNA-5p (miRNA-3p/−5p) pairs that frequently co-exist in cells remain largely unclear. In this study, we explored...
Watanabe, Shiro Inoue, Tetsuya Okamoto, Shozo Magota, Keiichi Takayanagi, Ayumi Sakakibara-Konishi, Jun Katoh, Norio Hirata, Kenji Manabe, Osamu Toyonaga, Takuya
...
Published in
EJNMMI Research
BackgroundWe investigated the prognostic predictive value of the combination of fluorodeoxyglucose (FDG)- and fluoromisonidazole (FMISO)-PET in patients with non-small cell lung carcinoma (NSCLC) treated with stereotactic body radiation therapy (SBRT).Patients and methodsWe prospectively examined patients with pathologically proven NSCLC; all under...
Zhu, Junfei Wang, Lili Liao, Ruomin
Published in
Artificial cells, nanomedicine, and biotechnology
We aimed to determine the roles and possible mechanism of long non-coding RNA SDPR-AS in the processes of non-small cell lung cancer (NSCLC). The expressions of SDPR-AS and SDPR in different subtypes of lung cancer (AC, SCC, LCC and SCLC) tissues and cells were determined. Three NSCLC cells were infused with pcDNA-SDPR-AS, pcDNA3.1, sh-SDPR-AS, sh-...
Hasegawa, Tsukasa Yanagitani, Noriko Utsumi, Hirofumi Wakui, Hiroshi Sakamoto, Hiroaki Tozuka, Takehiro Yoshida, Hiroshi Amino, Yoshiaki Uematsu, Shinya Yoshizawa, Takahiro
...
Published in
Anticancer research
This study aimed to determine whether the neutrophil-to-lymphocyte ratio (NLR) reflected poor treatment benefits in patients with tumor proportion score (TPS) ≥50% and who under went first-line pembrolizumab monotherapy. This study retrospectively analyzed patients with untreated stage III/IV or recurrent non-small cell lung cancer (NSCLC) with TPS...
Van Damme, Eufra Kiselinova, Maja Van Schoote, Elke
Published in
Tumori
Anaplastic lymphoma kinase (ALK) gene translocation occurs in 3%-5% of patients with non-small cell lung cancer (NSCLC), typically in younger patients. Crizotinib (tyrosine kinase inhibitor) has been considered as the standard of care for advanced ALK-positive lung cancer but it only gives a median progression-free survival of 7.7-11 months. A 41-y...
